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ABSTRACT:
The development of lethal, castration resistant prostate cancer is associated 
with adaptive changes to the androgen receptor (AR), including the emergence of 
mutant receptors and truncated, constitutively active AR variants. AR relies on the 
molecular chaperone HSP90 for its function in both normal and malignant prostate 
cells, but the requirement for HSP90 in environments with aberrant AR expression 
is largely unknown. Here, we investigated the efficacy of three HSP90 inhibitors, 
17-AAG, HSP990 and AUY922, against clinically-relevant AR missense mutants and 
truncated variants. HSP90 inhibition effectively suppressed the signaling of wild-type 
AR and all AR missense mutants tested. By contrast, two truncated AR variants, AR-
V7 and ARv567es, exhibited marked resistance to HSP90 inhibitors. Supporting this 
observation, nuclear localization of the truncated AR variants was not affected by 
HSP90 inhibition and AR variant:HSP90 complexes could not be detected in prostate 
cancer cells. Interestingly, HSP90 inhibition resulted in accumulation of AR-V7 
and ARv567es in both cell lines and human tumor explants. Despite the apparent 
independence of AR variants from HSP90 and their treatment-associated induction, 
the growth of cell lines with endogenous or enforced expression of AR-V7 or ARv567es 
remained highly sensitive to AUY922. This study demonstrates that functional AR 
variant signaling does not confer resistance to HSP90 inhibition, yields insight into 
the interaction between AR and HSP90 and provides further impetus for the clinical 
application of HSP90 inhibitors in advanced prostate cancer.
INTRODUCTION
The mechanisms underlying the development of 
castration-resistant prostate cancer (CRPC), characterized 
by the survival and proliferation of prostate cancer cells 
following androgen deprivation therapy (ADT), have 
been the subject of intense scrutiny over the past decade. 
The totality of research in this field has demonstrated that 
CRPC is characterized by sustained androgen receptor 
(AR) signaling within the “castrate” environment [1] 
through adaptive mechanisms such as increased intra-
tumoral androgen biosynthesis [2], AR overexpression and 
amplification [3, 4] and increased response to or levels 
of AR co-regulators [5]. Another important mechanism 
driving castration-resistance is mutation of the AR gene, 
the frequency of which increases with tumor stage and 
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in CRPC [6-8]. Functional analyses have demonstrated 
that the majority of these mutations do not cause loss of 
function but rather confer one of two main phenotypes: 
increased promiscuity of activation by non-classical 
ligands, or greater transactivation capacity via altered 
interaction with co-regulators. Archetypal examples 
include the T877A mutation, which is present in the 
LNCaP cell line and allows promiscuous activation by a 
variety of hormonal ligands [9], and the E235G mutation 
(E231G in mice), which increases basal receptor activity, 
affects co-regulator binding and yields a receptor that can 
cause oncogenic transformation of the prostate [10]. 
More recently, the isolation of constitutively active, 
truncated forms of the AR has revealed another mechanism 
underlying persistent AR signaling in CRPC. These so-
called AR variants (ARVs), which arise due to aberrant 
splicing and/or structural rearrangements of the AR gene 
[11, 12], have variable structures but each lacks all or a 
portion of the ligand-binding domain (LBD) [13]. Loss of 
the LBD produces transcription factors that can signal in 
the absence of ligand and are therefore resistant to LBD-
targeting AR antagonists or agents that repress androgen 
biosynthesis [12, 14-16]. Two of the most commonly 
occurring variants, ARv567es and AR-V7, are induced 
by castration and their expression in bone metastases of 
men with CRPC is associated with a particularly poor 
prognosis [12, 17, 18]. These observations suggest that 
ARVs represent an adaptive response to ADT by enabling 
sustained growth-promoting signaling in an androgen-
deplete environment. A mechanism potentially underlying 
the association of ARVs with lethal disease was recently 
elucidated by Hu and colleagues, who showed that 
ARVs direct the expression of a transcriptome that is 
characterized by genes involved in mitosis and rapid 
progression through DNA-repair check points [19]. 
The realization that AR signaling is maintained 
in CRPC has underpinned the clinical development and 
recent FDA approval of agents that more effectively target 
androgen biosynthesis (e.g. abiraterone acetate) or the AR 
LBD (e.g. MDV3100/enzalutamide). While abiraterone 
and enzalutamide have improved the clinical outlook of 
men with CRPC, they are not curative [20, 21]. As with 
earlier forms of ADT, resistance to these newer generation 
agents may involve the emergence of novel forms of 
the AR, including point mutants and truncated variants 
[19]. As such, there is an urgent requirement for novel 
therapeutic strategies for CRPC that effectively inhibit all 
forms of aberrant AR signaling. 
Heat shock protein 90 (HSP90) is an ATP-dependent 
molecular chaperone required for the stabilization and 
correct folding of > 200 proteins [22]. These “clients” 
include AR and a range of oncoproteins involved in 
diverse cellular pathways, making it an attractive target for 
prostate cancer [23, 24]. Moreover, HSP90 is frequently 
elevated in malignant prostate tissue compared to normal 
epithelium, highlighting its clinical relevance [25]. A 
number of recent studies have demonstrated the pre-
clinical efficacy of HSP90 inhibitors in prostate cancer, 
including an ability to delay castration-resistant tumor 
growth [26-29]. The most extensively characterized 
HSP90 inhibitors are the ansamycin derivatives, 
including 17-allylamino-17 demethoxygeldanamycin 
(17-AAG) and 17-(dimethylaminotheyl-amino)-17-
demethoxygeldanamycin (17-DMAG), which have 
performed poorly in the clinic due to poor solubility 
and pharmacokinetics and hepatotoxicity [30, 31]. 
Newer-generation agents such as NVP-AUY922 
(hereafter referred to as AUY922), a resorcinylic 
isoxazole amide, and NVP-HSP990 (HSP990), an orally 
available aminopyrimidine, possess more favourable 
pharmacological properties and are currently being 
assessed in multiple clinical trials (www.clinicaltrials.
gov). 
Despite the potential of HSP90 inhibitors for the 
treatment of prostate cancer, the consequence of HSP90 
inhibition has not been comprehensively assessed in 
the context of AR signaling by aberrant forms of the 
receptor, such as gain-of-function missense mutants and 
constitutively-active variants lacking the LBD. This is 
of particular relevance given the emerging realization 
that HSP90 and other chaperones act to stabilize mutant 
oncoproteins that are characteristic of many human 
cancers [23, 24]. In this study, we examined the efficacy 
of HSP90 inhibitors against a diverse range of androgen 
receptor mutants and variants. Our work further highlights 
the clinical potential of these agents in prostate cancer 
and provides insight into the chaperone requirements of 
aberrant androgen receptors.
RESULTS
HSP90 inhibitors repress the transcriptional 
activity of wild-type AR and a wide range of 
clinically-relevant AR mutants
HSP90 inhibitors, 17-AAG, AUY922 and HSP990, 
were assessed for their ability to decrease wild-type AR 
(wtAR) transactivation activity by luciferase reporter 
assay in transfected PC-3 prostate cancer cells. All three 
HSP90 inhibitors dose-dependently decreased wtAR 
transactivation activity but AUY922 was the most 
potent agent, reducing wtAR transactivation activity by 
>98% at doses of 25nM and above (Fig. 1, top left). The 
efficacy of the HSP90 inhibitors were then assessed in 
cells transfected with a range of somatic missense gain-
of-function AR point mutants that have been previously 
identified in clinical prostate tumors, mouse models, 
xenografts and cell lines (Supplementary Table 1). We 
first confirmed that each of the mutants were expressed at 
a similar level to wtAR and exhibited comparable DHT-
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Figure 1: HSP90 inhibitors dose-dependently reduce transactivation activity of wtAR and gain-of-function missense 
mutants. PC-3 cells were transfected with plasmids expressing wtAR or AR mutants and a probasin-luciferase reporter for 4 h prior to a 
20 h treatment with 1 nM DHT. The doses of HSP90 inhibitor are shown to the right of the graphs. Luciferase activity values are expressed 
relative to 0 nM HSP90 inhibitor (set to 100%) and represent the mean (± SEM) of two independent experiments.
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dependent transcriptional activity (Supplementary Fig. 1). 
In response to HSP90 inhibitor treatment, all 7 AR mutants 
displayed a dose-dependent decrease in transactivation 
activity (Fig. 1). As observed for wtAR, AUY922 was 
consistently the most potent HSP90 inhibitor, reducing 
transactivation activity of all assayed AR mutants by 60-
90% at ≥ 25 nM dose. 
The transcriptional activity of AR variants 
lacking the LBD is resistant to HSP90 inhibition
We next assessed the effect of HSP90 inhibition 
on transcriptional signaling by the two most clinically 
relevant ARVs, ARv567es and AR-V7. Both of these 
Figure 2: Truncated AR variants exhibit resistance to HSP90 inhibitors. Transactivation assays were performed as described 
in Figure 1 with low doses of HSP90 inhibitors (A) or high doses of HSP90 inhibitors (B) (keys are shown below the graphs). Lysates not 
analyzed for luciferase activity were pooled from replicate wells and immunoblotted for AR and GAPDH to visualize steady-state protein 
levels. 
AR-V7
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variants lack the LBD, are active in the absence of 
androgen, and are resistant to drugs targeting the LBD 
[12, 19]. As expected, in our experimental system the 
variants could activate the synthetic probasin promoter in 
an androgen-independent manner (Supplementary Fig. 2). 
Interestingly, both truncated AR variants exhibited marked 
resistance to HSP90 inhibition compared to the full-length 
receptor (Fig. 2A). More specifically, doses up to 100 nM 
of 17-AAG had no effect on AR-V7 transactivation and no 
dose of AUY922 or HSP990 reduced either ARv567es or 
AR-V7 by more than ~ 60%. 
Inhibition of HSP90 function is known to induce 
proteosomal degradation of HSP90 client proteins, 
including AR [32]. To determine whether the divergent 
responses to HSP90 inhibition were associated with 
changes in steady-state protein levels, lysates utilized in 
the luciferase assays were analyzed by immunoblotting. 
Protein levels of wtAR decreased in a dose-dependent 
manner in response to HSP90 inhibition and generally 
corresponded well with transcriptional activity (Fig. 2A). 
By contrast, steady-state protein levels of the variants 
were reduced by HSP90 inhibition but not to the extent of 
wtAR. Furthermore, in some cases robust transcriptional 
activity could be observed even when variant protein was 
effectively reduced by HSP90 inhibition (see, for example, 
response of AR-V7 and ARv567es to 100 nM doses of 
HSP990). 
To assess the extent to which the constitutively-
Figure 3: HSP90 inhibition does not affect the nuclear localization of truncated AR variants. PC-3 cells grown in androgen-
depleted media (phenol-red free RPMI + DCC-FBS) were transfected with GFP-tagged forms of wtAR (A), AR v567es (B) or AR-V7 (C) 
and treated with DMSO (vehicle control), 1 nM DHT or 1 nM DHT and 100 nM AUY922. Nuclei were stained with DAPI and cytoskeletons 
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active AR variants were resistant to HSP90 inhibition, 
the transactivation assays were repeated at 10-fold higher 
doses of HSP90 inhibitor (0-1000 nM). No transcriptional 
activity by wtAR was observed for any AUY922 dose 
or any HSP990 treatment ≥ 250nM, an observation that 
mirrored receptor protein levels (Fig. 2B). The reduction 
in wtAR activity and protein was not due to a decrease 
in cell number within the timeframe of the experiment, 
as assessed by crystal violet assay (Supplementary Fig. 
3). Interestingly, even with high doses of the HSP90 
inhibitors, ARv567es and AR-V7 exhibited robust 
transcriptional activity: no dose of any HSP90 inhibitor 
reduced AR-V7 activity more than ~ 60%, whereas 
ARv567es was slightly more sensitive but still maintained 
> 20% of its normal activity at the highest doses (Fig. 
2B). Moreover, we noted that treatment with doses of 
AUY922 greater than 250 nM resulted in a modest but 
reproducible recovery of ARV transactivation activity that 
was associated with increased protein levels (Fig. 2B).
ARVs function independently of the HSP90 
chaperone system
To further investigate the apparent resistance of 
ARv567es and AR-V7 to these agents, we determined 
whether HSP90 inhibition affected the subcellular 
localization of GFP-tagged forms of the variants. We 
first confirmed that GFP-wtAR, GFP-AR-V7 and GFP-
ARv567es were transcriptionally active in PC-3 cells 
(Supplementary Fig. 4A). Subsequently, cells expressing 
the fusion proteins were treated with DHT and/or AUY922 
and fluorescence monitored after 48 h. Wild-type AR 
was primarily cytoplasmic when cells were grown in the 
absence of androgen (charcoal-stripped serum) and shifted 
rapidly to the nucleus with addition of DHT (Fig. 3A). 
However, co-treatment with AUY922 blocked the DHT-
mediated nuclear import of wtAR (Fig. 3A). By contrast, 
AR-V7 and ARv567es exhibited primarily nuclear 
localization in the absence of DHT and this distribution 
was not altered when cells were treated with AUY922 
(Figs. 3B and 3C). Thus, nuclear import of ARVs appears 
to be independent of the HSP90 chaperone system. 
To further examine the relationship between 
ARVs and HSP90, we tested whether ARV:HSP90 
protein complexes exist in prostate cancer cells by 
co-immunoprecipitation assays. FLAG-tagged forms 
of wtAR and the ARVs, which exhibited normal 
transcriptional activity (Supplementary Fig. 4B), were 
used in this experiment. FLAG-AR was isolated by 
immunoprecipitation under non-denaturing conditions, 
and molybdate was included to preserve chaperone 
interactions [33].  As expected, wtAR formed a complex 
with HSP90 when grown in androgen-depleted media 
that was largely lost following the addition of 1 nM 
DHT (Fig. 4A). By contrast, neither of the AR variants 
co-immunoprecipitated detectable amounts of HSP90 in 
androgen-depleted media (Fig. 4B), further suggesting that 
classical AR regulatory mechanisms do not influence ARV 
function.
ARV expression is induced by HSP90 inhibition
Our results suggest that transiently-expressed ARVs 
function largely independently of the HSP90 chaperone. 
To assess whether HSP90 inhibitors affect the expression 
and/or stability of endogenously-expressed ARVs, protein 
and RNA was isolated from VCaP cells that had been 
treated for 24 h with AUY922. VCaP cells were chosen 
because they express both AR-V7 and ARv567es and 
exhibit selection of AR-V7 in response to agents targeting 
the LBD (e.g. MDV3100) [19]. qRT-PCR quantification 
revealed that full-length AR (detected with primers that 
amplify a region crossing the exon 5-6 splice junction) 
and AR-V7 expression increased in response to 40 and 
160 nM AUY922 treatment compared to vehicle control 
(DMSO) (Fig. 5A). In our hands, ARv567es mRNA was 
Figure 4: Truncated AR variants do not form stable complexes with HSP90. (A) DHT promotes dissociation of wild-type 
AR from HSP90. PC-3 cells grown in androgen-depleted media (phenol-red free RPMI + DCC-FBS) were transfected with FLAG-tagged 
wtAR or empty plasmid and treated with 1 nM DHT or vehicle control. FLAG-tagged wtAR protein complexes were immunoprecipitated 
and immunoblotted for HSP90. (B) Truncated AR variants do not associate with HSP90. PC-3 cells grown in androgen-depleted media were 
transfected with FLAG-tagged wtAR, ARv567es or AR-V7 or an empty plasmid control and grown in an androgen-depleted environment. 
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not detectable by Taqman probe-based qRT-PCR in this 
cell line (data not shown), possibly because cells were 
grown in media containing full serum and supplemented 
with 0.1% DHT, which is known to repress ARv567es 
expression [19]. Corresponding protein lysates were 
immunoblotted for AR to assess whether the observed 
changes in mRNA were coupled to an increase in protein 
level (Fig. 5B). Induction of HSP70, a known marker 
of HSP90 inhibition [26], confirmed the efficacy of the 
drug treatments (Fig. 5B). Importantly, AR-V7 protein 
levels were robustly increased following treatment with 
AUY922. Interestingly, loss of wtAR protein was not 
observed by HSP90 inhibition in VCaP cells, a response 
that is incongruent with other prostate cancer cell lines 
(e.g. LNCaP, C4-2B, 22Rv1) and tumor explants [26, 27, 
34, 35].  
To investigate the relationship between HSP90 
inhibition and ARV expression in a more biologically 
relevant system, we evaluated AR and ARV expression 
in human prostate tumors cultured ex vivo in medium 
containing AUY922. As previously observed [26], 
treatment of tumor tissue with AUY922 markedly reduced 
proliferation, as measured by Ki67 immunohistochemistry 
(Supplementary Fig. 5). We have previously demonstrated 
that AUY922 decreases wtAR protein levels in primary 
tumors cultured in this manner [26]. By contrast, wtAR 
mRNA levels increased in 9/9 tumors (average = 3.1-
fold) in response to treatment with 500 nM AUY922 
compared to vehicle control (DMSO) (Fig. 5C) (one sided 
t test, p = 0.0011). ARV expression was also induced by 
AUY922: ARv567es (detectable in 7/9 tumours) and AR-
V7 (detectable in 8/9 tumors) transcript levels increased 
by an average of 8.8-fold (p = 0.0493) and 1.6-fold (p = 
0.1170), respectively (Fig. 5C). These data reveal that in 
ex vivo cultured primary tumors, AUY922 induces full-
length AR and ARV mRNA expression concomitantly with 
inhibition of proliferation.
Growth of ARV-expressing prostate cancer cell 
lines is suppressed by HSP90 inhibition 
Given that ARVs are resistant to HSP90 inhibitors at 
a transcriptional level, can enter the nucleus independently 
of the HSP90 chaperone system and can be induced by 
AUY922 in primary tumors, we reasoned that persistent 
ARV-mediated signaling in prostate cancer cells could 
confer some level of resistance to HSP90 inhibition. To 
test this idea, we assessed the growth-suppressive activity 
of AUY922 in the VCaP line. As reported previously 
[26], these cells were sensitive to AUY922 treatment, 
with maximal anti-proliferative activity observed at 40 
nM (Fig. 6A). VCaP cells did not grow well in androgen-
deplete media and growth suppression by AUY922 could 
not be assessed under these conditions (data not shown).
We subsequently investigated the efficacy of 
AUY922 in another prostate cancer cell line with 
endogenous ARV expression, 22Rv1 [14]. The ability 
of 22Rv1 cells to grow in the absence of androgen or in 
the presence of enzalutamide (MDV3100) is conferred 
by expression of the AR-V7 variant [14, 36]. Cell 
proliferation was reduced in a dose-dependent manner by 
AUY922 in both androgen-replete (full fetal bovine serum 
(FBS)) and androgen-deplete (charcoal-stripped serum; 
DCC-FBS) media (Fig. 6B), where maximal inhibition 
was observed at 20 nM and 40 nM, respectively. 
To more directly investigate the potential of ARVs to 
promote resistance to AUY922, we generated LNCaP cells 
stably transfected with inducible forms of wtAR, AR-V7 
and ARv567es. Upon treatment with cumate, the proteins 
were expressed at levels approximately 1-5% of the 
Figure 5: AUY922 modulates the levels of wtAR and AR-V7 transcript and protein. (A) VCaP cells were treated for 24 h with 
the indicated doses of AUY922 or vehicle DMSO. Wild-type AR and AR-V7 mRNA was measured by quantitative RT-PCR (normalized to 
reference gene GAPDH; DMSO set to 1). Values are the mean (± SEM) of triplicate samples; results are representative of two independent 
experiments. (B) Lysates from cells treated in part A were collected and immunoblotted for wtAR (AR N-20; AR C-19), HSP70 or AR-
V7. GAPDH was used as a loading control. (C) Human prostate tumor explants were cultured in medium containing 500 nM AUY922 or 
vehicle DMSO for 48 h. Wild-type AR, AR-V7 and ARv567es mRNA was measured by quantitative RT-PCR (normalized to reference 
gene GAPDH; DMSO set to 1). Statistically significant differences compared to DMSO control treatment were assessed using one-sample 
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endogenous wtAR (Fig. 6C), a ratio that has been reported 
to be physiologically relevant [17]. In growth assays, 
robust induction of the proteins was observed after 4 days 
(Fig. 6C). As expected, AUY922 effectively suppressed 
the growth of LNCaP cells expressing physiological levels 
of wtAR (control line + ethanol/cumate; wtAR line + 
ethanol), and over-expression of wtAR following cumate 
treatment had no discernable impact on drug efficacy (Fig. 
6D). Similarly, enforced over-expression of AR-V7 or 
ARv567es did not confer any detectable level of resistance 
to HSP90 inhibition by AUY922 (Fig. 6D). 
DISCUSSION
Current treatments for CRPC prolong survival, 
but are not curative. The critical role of HSP90 in the 
stabilization, maturation and activation of AR and other 
proteins that contribute to the progression of prostate 
cancer highlights the potential of HSP90 inhibitors as 
therapeutic agents. However, until now, no study has 
comprehensively assessed whether clinically relevant 
gain-of-function AR mutants and truncated androgen 
receptors that can emerge in CRPC are reliant on the 
HSP90 chaperone system for activity.
Using AR-specific reporter assays, we found that 
HSP90 inhibition effectively disrupted the transcriptional 
activity of a wide range of clinically-relevant AR somatic 
missense point mutants. Therefore, as for wtAR, canonical 
HSP90 regulatory pathways are likely to control the 
maturation, stabilization, ligand binding and nuclear 
import of mutant receptors. This finding strengthens the 
case for the application of HSP90 inhibitors in castration-
resistant tumors, which are more likely to express gain-
of-function mutant receptors. As expected from IC50 
values, solubility and affinities for HSP90, AUY922 and 
HSP990 were more efficacious against the AR mutants 
than the ansamycin derivative, 17-AAG. This corresponds 
with previous work from our laboratory demonstrating 
enhanced efficacy of AUY922 and HSP990 in the 
LNCaP cell line that expresses the T877A mutation [26]. 
The increased capacity of these new generation agents 
to disrupt both wild-type and mutant AR signaling, in 
addition to their improved pharmacologic and toxicologic 
profiles, further supports their clinical investigation in men 
with advanced prostate cancer. 
In contrast to the missense AR mutants, the 
C-terminally truncated AR-V7 and ARv567es 
both displayed resistance to HSP90 inhibitors at a 
Figure 6: Prostate cancer cells expressing ARVs are sensitive to HSP90 inhibition. (A) AUY922 reduces cell viability of 
VCaP prostate cancer cells. Proliferation of cells cultured with increasing concentrations of AUY922 was assessed by trypan blue exclusion 
assays. Cells were grown in media containing 10% FBS + 0.1 nM DHT. (B) AUY922 reduces cell viability of 22Rv1 prostate cancer cells, 
as assessed  by trypan blue exclusion assays. Cells were grown in the presence of androgen (10% FBS; left) or in androgen-depleted media 
(10% DCC-FBS; right). (C) Induction of FLAG-ARVs by cumate in stably-transduced LNCaP cells. Western blots with FLAG antibody 
(M2; top) or AR antibody (N-20; bottom) are shown. (D) AUY922 reduces cell viability of LNCaP cells stably transfected with inducible 
expression constructs: empty (C), wtAR (wt), AR-V7 (V7) and ARv567es (v567). Cells were cultured in 10% FBS and treated with cumate 
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transcriptional level. Indeed, even doses up to 1000 
nM of AUY922 and HSP990 only partially disrupted 
ARV signaling. Similarly, a recent study found that 
the transcriptional activity of AR-V7 was shown to be 
resistant to other new and old-generation HSP90 inhibitors 
(ganetespib and geldanamycin, respectively) [37]. Two 
findings from our study likely underpin the apparent 
independence of ARV activity from HSP90. First, the 
nuclear localization of AR-V7 and ARv567es was largely 
unaffected by the potent HSP90 inhibitor, AUY922. This 
observation mirrors recent research demonstrating that 
the nuclear import of ARVs was not disrupted by 17-AAG 
[38]. By contrast, even in a cell line model of CRPC that 
exhibits ligand-independent activity of full-length AR, 
normal HSP90 function is necessary for nuclear import 
of the receptor [39], highlighting the distinction between 
ARVs and wtAR. Second, co-immunoprecipitation assays 
revealed that interactions between ARVs and HSP90 
are not detectable even in cells transiently expressing 
high levels of the ARV. Interaction surface mapping 
has demonstrated that chaperone interactions localize 
primarily to the LBD of steroid receptors [22]. More 
specifically, analysis of the rat AR found that amino 
acids 703 and 758 of the rat AR, corresponding to the 
hinge region and part of the LBD in the human AR, are 
important for its interaction with HSP90 [40]. Studies 
of the glucocorticoid receptor identified a specific 
7-amino acid sequence required for HSP90 binding that 
corresponds with amino acids 670 to 676 in the hinge 
domain of the human AR [41], which is a reported protein-
protein interaction surface [42]. ARv567es contains 
the hinge domain but none of the LBD whereas AR-V7 
lacks both the hinge and LBD, supporting a role for these 
C-terminal domains in mediating an interaction between 
full length AR and HSP90. 
Collectively, the observation that HSP90 inhibitors 
have a minimal effect on ARV transcriptional activity 
and nuclear localization and our inability to detect 
HSP90:ARV protein complexes indicate that AR-V7 and 
ARv567es function largely independently of HSP90. 
Whether other proteins “chaperone” ARVs is currently 
unknown. Classic members of the HSP90 molecular 
machinery, such as HSP70, p23, FKBP52 and Cyp40, 
either bind to the AR LBD or indirectly with AR via 
HSP90 [22, 43]. As such, we do not expect these factors 
to be important regulators of C-terminally truncated 
AR variants. A plausible candidate ARV chaperone is 
HSP27, which was found to bind directly to the AR NTD 
in vitro and has been linked to treatment resistance and 
cell survival in prostate cancer [44]. At least two lines 
of evidence support the concept that a non-canonical 
chaperone system, perhaps comprising HSP27 and/or 
other factors, regulates ARV function. First, by comparing 
the expression of full-length AR with ARVs at both 
the protein and mRNA level, Hornberg and colleagues 
found evidence for increased stability of ARVs in CRPC 
bone metastases [17]. Protection from intracellular 
protein surveillance mechanisms, such as the ubiquitin-
proteasome system, is a major function of HSPs and 
stress proteins. Second, the intrinsically disordered nature 
of the NTD means that chaperone-mediated protection 
from misfolding, aggregation and illicit protein:protein 
interactions would likely benefit ARVs. Identifying ARV 
regulators, including chaperones, is an important next 
step in elucidating the function of these novel drivers of 
prostate cancer progression and is likely to have significant 
clinical implications. 
While our discussion has focused on the resistance 
of ARVs to HSP90 inhibition, the observation that high 
doses of all three agents at least partially suppressed ARV-
driven transcription is worth consideration. We envision at 
least three possible explanations for this finding. First, we 
cannot rule out the possibility that ARVs retain a residual 
level of interaction with, and reliance on, HSP90. Indeed, 
a subset of the variants retain the hinge region, a proposed 
HSP90 interaction surface. Second, as discussed above, 
ARVs may utilize alternative chaperones that could be 
affected by high concentrations of HSP90 inhibitors. 
Finally, ARV activity is likely to be indirectly affected 
by HSP90 inhibition through deregulation of alternative 
client proteins. For example, it was recently found that 
suppression of the PI3K-AKT pathway inhibits AR-V7 
transcriptional activity [45], and HSP90 is an important 
regulator of AKT [46]. 
Despite the apparent autonomy of ARVs from 
the HSP90 chaperone system, we observed that the 
growth/proliferation of cell lines expressing AR-V7 or 
ARv567es, either endogenously or in an enforced manner 
from an inducible promoter, is highly sensitive to HSP90 
inhibition. Thus, the growth advantage associated with 
ARV expression is unable to compensate for disruption 
of other critical cellular pathways by HSP90 inhibitors. 
It follows that sensitivity to these agents is largely 
independent from both classical and aberrant AR signaling 
axes, a concept further supported by the observation that 
HSP90 inhibitors are highly effective in both AR-positive 
and AR-negative settings in vitro [26]. Collectively, these 
findings highlight the broad mode of action of these 
agents, a characteristic also likely to minimize the therapy-
mediated selection pressures that drive drug resistance. 
This study also provided insight into the relationship 
between HSP90 inhibition and AR gene expression. 
Importantly, we demonstrated that treatment with the 
potent HSP90 inhibitor AUY922 caused an increased 
level of transcripts encoding full-length AR (VCaP cells 
and primary tumors), AR-V7 (VCaP cells only; trend 
to increase in primary tumors) and ARv567es (primary 
tumors only; not detectable in VCaP cells). One potential 
explanation for this finding is that liganded AR can 
negatively regulate its own expression [47]: thus, the 
loss of AR protein associated with HSP90 inhibition, 
which occurs in AUY922-treated, ex vivo cultured 
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prostate tumors [26], could de-repress the AR gene. 
This hypothesis may also explain why AR inhibition 
(MDV3100 treatment or knockdown with siRNA) leads to 
accumulation of AR-V7 and emergence of an alternative 
transcriptome [19]. Alternatively, HSP90 inhibition may 
impact on mRNA splicing, stability and/or translation, 
leading to accumulation of AR mRNA [48]. Irrespective 
of mechanism, the finding that HSP90 inhibitors can cause 
accumulation of AR and ARVs may be relevant to the 
clinical application of these agents. For example, although 
we have demonstrated that the broad mode of action of 
HSP90 inhibitors can overcome the selection for ARVs in 
short-term in vitro experiments, the consequences of such 
selection during prolonged treatment of men is unknown. 
Our findings provide a rationale for clinical application 
of a combinatorial treatment strategy comprising HSP90 
inhibitors and agents that target the AR-NTD. 
AR-V7 and ARv567es were detectable by qRT-
PCR in 8/9 and 7/9 primary tumors, respectively. For AR-
V7, this proportion is similar to what has been reported 
in previous studies [16, 17]. By contrast, ARv567es has 
rarely been detected in primary tumors to date [12, 17]. 
A possible explanation for this discrepancy relates to 
methodology: we employed a highly specific probe-based 
assay rather than the SYBR assay employed in earlier 
studies. Our data suggests that ARv567es may be more 
prevalent than previously estimated, an important finding 
given its association with survival [17].
In summary, our study provides key new insights 
into the clinical potential of HSP90 inhibitors in cells that 
are characterized by aberrant AR signaling. Despite the 
independence of constitutively-active AR variants from 
the HSP90 chaperone system, HSP90 inhibitors are likely 
to be effective in CRPC by targeting signaling by wild-
type AR, missense AR mutants and other critical pathways 
required for growth and survival of prostate cancer cells.   
MATERIALS AND METHODS
Reagents and antibodies
AUY922 and HSP990 were obtained from Novartis 
and dissolved in dimethyl sulfoxide (DMSO). 17-
AAG and MDV3100 were obtained from the National 
Cancer Institute and Sellicks Chemicals, respectively, 
and dissolved in DMSO. Primary antibodies used for 
Western blotting were AR-N20 (1:1000; SC-816, Santa 
Cruz Biotechnology Inc), AR-V7 (1:500; AG10008, 
Precision Antibody), HSP70 (1:1000; SPA-812, Stressgen 
Bioreagents), HSP90α/β (1:1000; SC-7947, Santa Cruz), 
GAPDH (1:2000; MAB374, Millipore) and FLAG 
(1:2000; M2, Sigma). A tubulin antibody (1:2500; 05-829, 





has been reported [32]. Plasmid constructs harbouring 
full-length AR with somatic missense mutations were 
created from pCMV-AR by PCR-based megaprimer in 
vitro mutagenesis as previously described [33]. pcDNA-
AR-V7 and pcDNA-ARv567es expression plasmids have 
been described [19]. pcDNA-HA-GFP-ARv567es was 
made by inserting a PCR product containing the complete 
GFP coding sequence into the BamHI site of pcDNA-
HA-ARv567es [12]. pEGFP-AR-V7 and pEGFP-AR 
were generously provided by M. Marcelli [34]. pCMV-
3xFLAG-AR, pCMV-3xFLAG-V7 and pCMV-3xFLAG-
v567es were made by ligating AR and ARV PCR products 
into the EcoRI/XbaI sites of p3xFLAG-CMV-9 (Sigma). 
3xFLAG-AR fragments were also inserted into the pCDH-
EF1-CymR-T2A-Puro vector (System Biosciences).
Cell lines
VCaP, PC-3 and 22Rv1 human prostate carcinoma 
cells were obtained from the American Type Culture 
Collection. All cell lines underwent verification by short-
tandem repeat profiling in 2010 by CellBank Australia. 
PC-3 cells were maintained in RPMI-1640 containing 5% 
FBS or phenol-red free RPMI  containing 5% charcoal-
stripped serum (DCC-FBS). 22Rv1 cells were maintained 
in RPMI-1640 containing 10% FBS or phenol-red free 
RPMI  containing 10% charcoal-stripped serum (DCC-
FBS). VCaP cells were maintained in Dulbecco’s Modified 
Eagle’s Medium containing 10% FBS, 1% sodium 
pyruvate, 1% MEM non–essential amino acids, and 0.1 
nM 5α-dihydrotestosterone (DHT; Sigma). LNCaP lines 
expressing cumate-inducible 3xFLAG-wtAR, 3xFLAG-
ARv567es and 3xFLAG-AR-V7 lentivirus were made 
using the SparQ cumate switch lentivector system 
(Systems Biosciences). pCDH-EF1-CymR-T2A-Puro 
vectors were packaged into lentiviral particles using 
pPACK packaging systems (System Biosciences). To 
make stable cell lines, LNCaP cells were infected with 1 x 
107 virus particles per 1 x 106 cells then selected with 1 ug/
ml puromycin (Invitrogen) for 10 days. Stably transduced 
LNCaP lines were maintained in RPMI-1640 containing 
10% FBS.
Luciferase transactivation assays
AR transactivation assays were performed 
essentially as described [32]. Briefly, AR-negative PC-3 
prostate cancer cells were seeded in 96-well plates (1.5 
x 104 cells/well) and then transfected with 100 ng of 
pGL
4.14
-probasin-ARR3-tk-luciferase reporter plasmid and 
1.5 ng of the appropriate AR expression construct using 
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Lipofectamine 2000 (Invitrogen). Plasmid quantities were 
chosen to ensure receptor activity was within the linear 
range. After 4 h, treatment media containing HSP90 
inhibitor (0-1000 nM) and 1 nM DHT (Sigma) was added 
to the cells. Cells were lysed 24 h later with Passive Lysis 
Buffer (Promega) and frozen overnight at -80ºC. Lysates 
were assayed for luciferase activity using the Luciferase 
Assay System (Promega) and a plate reading luminometer 
(TopCount; Packard). Subsequently, protein from six 
replicate wells was pooled, centrifuged at 10,000g for 10 
min at 4ºC, and equal volumes of the supernatants were 
analyzed by SDS-PAGE and Western blotting.
Visualization of GFP-tagged proteins
PC-3 cells were seeded at a density of 3.0 x 104 
cells/well in 8-well Lab-Tek chamber slides (Nunc) and 
left overnight to adhere. The cells were then transfected 
with plasmids expressing GFP-tagged AR, AR-V7 and 
ARv567es using Lipofectamine 2000. After 24 h the 
cells were treated with AUY922 or DMSO (vehicle 
control) for 1 h in the absence or presence of 1nM DHT 
or ethanol (vehicle control). The cells were then fixed 
using 4% paraformaldehyde, washed with PBS and 
incubated overnight at 4ºC with an antibody specific for 
tubulin. Alexa-Fluor 594 donkey anti-mouse IgG (Life 
Technologies) was used to visualize tubulin staining. 
ProLong Gold Antifade Reagent with DAPI (Life 
Technologies) was used as mounting media and to detect 
cell nuclei. Cells were viewed using an Olympus IX71 
fluorescent microscope and images were obtained with 
an Olympus DP70 cooled digital color camera at 20x 
magnification.
Co-immunoprecipitation
AR:HSP90 complexes were isolated by 
immunoprecipitation as described previously [35]. 
Briefly, androgen-starved PC-3 cells were transfected 
with constructs expressing FLAG-tagged wild-type AR or 
ARVs using Lipofectamine 2000 (Invitrogen) for 4 h. The 
cells were treated 24 h later with vehicle (0.1% ethanol) 
or 1 nM DHT (Sigma) for 1 h in 5% DCC-FBS phenol-red 
free RPMI, then lysed in 500 μl IP buffer (20 mM Tris HCl 
(pH 7.5), 50 mM NaCl, 20 mM Na2MoO4, 0.5% NP-40 
Alternative, 1 mM EDTA, 1 mM EGTA (pH 8.0), 2 mM 
DTT and protease inhibitors). The lysates were sonicated 
twice at low power for 15 sec each (Bioruptor; Diagenode) 
and cleared by centrifugation (10 min, 16,000g at 4ºC). 
Samples were immunoprecipitated for 2 h with rotation 
at 4°C using anti-FLAG M2 agarose beads (Sigma) and 
then washed three times with IP buffer. Protein was eluted 
by boiling in SDS-PAGE loading buffer for 5 min and 
analyzed by SDS-PAGE and Western blotting.
Cell growth assays
Trypan blue exclusion counts were performed on 
22Rv1 and VCaP cells treated with AUY922. Growth 
assays were stopped when DMSO-treated cells reached 
the stationary phase of growth.  For LNCaP lines with 
inducible AR and ARV expression, cells were seeded out 
at 2 x 104 cells/well in 24-well plates. The next day, day 
zero counts were taken and cells were treated with 0.3 ug/
ml cumate to induce AR and ARV expression. One day 
later, cells were treated as appropriate with AUY922 or 
DMSO (control). Cells were counted after a further 72 
hours using trypan blue exclusion assays.
Ex vivo culture of human prostate tumors
Fresh prostate cancer specimens were obtained with 
written informed consent through the Australian Prostate 
Cancer BioResource from men undergoing robotic radical 
prostatectomy at the Royal Adelaide Hospital. Tissues 
were dissected and cultured as described previously [26] 
in medium containing DMSO or 500 nM AUY922. After 
48 h of culture, tissues were snap frozen and stored at 
-80oC. 
RNA extraction and quantitative real-time RT-
PCR
For cell line experiments, VCaP cells were 
seeded at a density of 4 x 105 cells/well in 12 well 
plates and treated for 24 h with AUY922 (40 or 160 
nM) or DMSO. RNA was extracted using Trizol using 
standard techniques. For prostate tumors, samples were 
homogenized using a Precellys tissue homogenizer 
(Bertin Technologies) or mortar and pestle and RNA 
was extracted using Trizol. 200 ng of RNA was reverse 
transcribed and analyzed by SYBR green qRT-PCR as 
described previously [36]. Primers for full-length AR 
(forward: CCTGGCTTCCGCAACTTACAC; reverse: 
GGACTTGTGCATGCGGTACTCA) amplify a region 
spanning exons 5 and 6, which is not found in C-terminally 
truncated AR variants. Primers for AR-V7 have been 
described previously [16]. Taqman qRT-PCR was used to 
quantify ARv567es using the following primers and probe 




Changes in the expression level of AR and AR-V7 
in VCaP cells treated with AUY922 were assessed using 
one-way ANOVA with Tukey’s post hoc test. Changes in 
the expression level of AR and ARVs in tumor explants 
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treated with AUY922 were assessed using a one-sample 
t test (where the control treatment, DMSO, was set to the 
hypothetical mean of 1). All statistical analyses were done 
using GraphPad Prism Software.
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